June 24, 2021
6:00 pm - 7:00 pm
WEBINAR 2: Thursday, June 24 – 6PM CT
UTERINE FIBROIDS & Elagolix+Estradiol/NETA, indicated for heavy menstrual bleeding associated with uterine leiomyomas in pre-menopausal women
Uterine fibroids, also called leiomyomas, are estrogen and progesterone-dependent non-cancerous tumors of the uterus and are the most common type of benign tumor in women of reproductive age. Traditionally, uterine fibroids have been primarily managed by surgery and are the leading reason for the hysterectomies performed in the U.S. ORIAHNN (Elagolix+Estradiol/NETA) is the first FDA-approved non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
This presentation will provide a brief scientific overview of disease state and clinical trial data for Elagolix+E2/NETA, indicated for heavy menstrual bleeding associated with fibroids (FDA approved May 2020). https://www.rxabbvie.com/pdf/oriahnn_pi.pdf